Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 401–500 of 1,025
Improvement of Gold Nanorods in Photothermal Therapy: Recent Progress and Perspective
Liao, S., Yue, W., Cai, S., Tang, Q., Lu, W., Huang, L., Qi, T., & Liao, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.664123 · Cited by 137
Developing High-Fidelity Hepatotoxicity Models From Pluripotent Stem Cells
Medine, C. N., Lucendo-Villarin, B., Storck, C., Wang, F., Szkolnicka, D., Khan, F., Pernagallo, S., Black, J. R., Marriage, H. M., Ross, J. A., et al. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0138 · Cited by 135
Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs
Poovi, G., & Narayanasamy, D. (2018) · Future Journal of Pharmaceutical Sciences · doi:10.1016/j.fjps.2018.04.001 · Cited by 151
ADMETboost: a web server for accurate ADMET prediction
Tian, H., Ketkar, R., & Tao, P. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-022-05373-8 · Cited by 155
“It was reported that many clinical trials fail due to the deficiencies in ADMET properties [13, 15, 17, 28].”
BackgroundWong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133
“The discovery and development of new drugs is a challenging process and finding new anticancer agents is particularly difficult (1).”
BackgroundProteome-Wide Analyses of Human Hepatocytes During Differentiation and Dedifferentiation
Rowe, C., Gerrard, D. T., Jenkins, R., Berry, A., Durkin, K., Sundstrom, L., Goldring, C. E., Park, K. B., Kitteringham, N. R., Hanley, K. P., et al. (2013) · Hepatology · doi:10.1002/hep.26414 · Cited by 133
“In addition to enormous expense,(2) it causes adverse events leading to patient morbidity and mortality.(3) This demands more predictive in vitro models for use early during drug development alongside in vivo testing in rodents.”
BackgroundSystems Pharmacology to Predict Drug Toxicity: Integration Across Levels of Biological Organization
Bai, J. P. F., & Abernethy, D. R. (2012) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140248 · Cited by 143
Nadanaciva, S., Bernal, A. J., Aggeler, R. J., Capaldi, R., & Will, Y. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.01.011 · Cited by 133
“It is also widely estimated that, on average, the launch of a drug in the US requires a decade of R&D, and costs approximately $800 million–1 billion (Kola and Landis, 2004).”
BackgroundEmerging trends in organ-on-a-chip systems for drug screening
Wang, Y., Gao, Y., Pan, Y., Zhou, D., Liu, Y., Yin, Y., Yang, J., Wang, Y., & Song, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.006 · Cited by 127
Mordwinkin, N. M., Burridge, P. W., & Wu, J. C. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9423-2 · Cited by 128
Target Validation: Linking Target and Chemical Properties to Desired Product Profile
Wyatt, P. G., Gilbert, I. H., Read, K. D., & Fairlamb, A. H. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795429185 · Cited by 131
“The result has been dramatic, and by the turn of the century, attrition had been significantly reduced in the clinic due to adverse PK and poor bioavailability [57].”
BackgroundAbdul‐Rahman, T., Ghosh, S., Badar, S. M., Nazir, A., Bamigbade, G. B., Aji, N., Roy, P., kachani, H., Garg, N. K., Lawal, L., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-01711-z · Cited by 149
Mouse hospital and co-clinical trial project—from bench to bedside
Clohessy, J. G., & Pandolfi, P. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.62 · Cited by 141
Modeling the blood–brain barrier using stem cell sources
Lippmann, E. S., Al-Ahmad, A., Palecek, S. P., & Shusta, E. V. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-2 · Cited by 122
“Compounds screened in animals or against cell lines often fail in clinical trials due to toxicity or a lack of efficacy [93], which highlights the need for improved model systems for drug screening.”
Do molecularly targeted agents in oncology have reduced attrition rates?
Walker, I., & Newell, H. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2758 · Cited by 150
Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129
Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning
Ye, H., Liu, Q., & Jia, W. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087864 · Cited by 139
“The inefficiency of pharmaceutical drug development with high expenditure but low productivity has been widely discussed [1,2,3,4].”
BackgroundModeling Barrier Tissues In Vitro: Methods, Achievements, and Challenges
Sakolish, C. M., Esch, M. B., Hickman, J. J., Shuler, M. L., & Mahler, G. J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.023 · Cited by 123
“issues (Kola and Landis, 2004), and testing methods have not changed significantly since then.”
The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review
Ambrosini, Y. M., Borcherding, D., Kanthasamy, A., Kim, H. J., Willette, A. A., Jergens, A., Allenspach, K., & Mochel, J. P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00130 · Cited by 126
Barriers to new drug development in respiratory disease
Barnes, P. J., Bonini, S., Seeger, W., Belvisi, M. G., Ward, B., & Holmes, A. M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00007915 · Cited by 139
Applications of tumor chip technology
Hachey, S. J., & Hughes, C. C. W. (2018) · Lab on a Chip · doi:10.1039/c8lc00330k · Cited by 128
Rosso, M., Wirz, R., Loretan, A. V., Sutter, N., da Cunha, C. T. P., Jarić, I., Würbel, H., & Voelkl, B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104928 · Cited by 141
“Translational failure can slow down medical advancement in the treatment of human disorders (Kola and Landis 2004; Hay et al. 2014; Leenaars et al. 2019), put patients in clinical trials at risk (Henderson et al.”
BackgroundBenfenati, E., Benigni, R., DeMarini, D. M., Helma, C., Kirkland, D., Martin, T. M., Mazzatorta, P., Ouédraogo, G., RICHARD, A. M., Schilter, B., et al. (2009) · Journal of Environmental Science and Health Part C · doi:10.1080/10590500902885593 · Cited by 129
“An overall reduction in the attrition rate of compounds with 20% to 50% failure rates by means of introducing early toxicity screening might lead to a sharp cost reduction in drug development ( 29 , 30 , 31 ).”
BackgroundInduced Pluripotent Stem Cells in Cardiovascular Drug Discovery
Mercola, M., Colas, A., & Willems, E. (2013) · Circulation Research · doi:10.1161/circresaha.111.250266 · Cited by 122
“Although this approach has been very successful over the past decade in developing drugs against well-characterized targets, it carries the risk that drugs that emerge from satisfying the constraints of target and MMOA may not be effective therapeutically, and this has been proposed to contribute to the high rate of d…”
BackgroundTargeting Intestinal Transporters for Optimizing Oral Drug Absorption
Varma, M. V. S., Ambler, C. M., Ullah, M., Rotter, C. J., Sun, H., Litchfield, J., Fenner, K. S., & El‐Kattan, A. F. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328850 · Cited by 138
The potential of high‐content high‐throughput microscopy in drug discovery
Starkuviene, V., & Pepperkok, R. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707346 · Cited by 147
“development (Kola and Landis, 2004).”
BackgroundHow can attrition rates be reduced in cancer drug discovery?
Moreno, L., & Pearson, A. D. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.768984 · Cited by 143
“Less than 5% of drugs that reach Phase I gain a marketing authorisation (MA) [2].”
BackgroundRuigrok, M. J. R., & de Lange, E. C. M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9724-x · Cited by 120
“(2008) (22) [Ser( (2))] exendin (1–9) Mice”
BackgroundInfluentialPredictive validity in drug discovery: what it is, why it matters and how to improve it
Scannell, J. W., Bosley, J., Hickman, J. A., Dawson, G. R., Truebel, H., Ferreira, G. S., Richards, D. B., & Treherne, J. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00552-x · Cited by 143
Integration of phytochemicals and phytotherapy into cancer precision medicine
Efferth, T., Saeed, M. E. M., Mirghani, E., Alim, A., Yassin, Z., Saeed, E. M., Khalid, H. E., & Daak, S. (2017) · Oncotarget · doi:10.18632/oncotarget.17466 · Cited by 143
Ye, Z., Yang, Y., Li, X., Cao, D., & Ouyang, D. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00816 · Cited by 125
Ivanenkov, Y. A., Zagribelnyy, B. A., & Aladinskiy, V. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00004 · Cited by 121
Design, synthesis and ADMET prediction of bis-benzimidazole as anticancer agent
Rashid, M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103576 · Cited by 126
Yamaguchi, S., Kaneko, M., & Narukawa, M. (2021) · Clinical and Translational Science · doi:10.1111/cts.12980 · Cited by 143
Paoloni, M. C., & Khanna, C. (2007) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2007.08.003 · Cited by 125
Sala, L., Bellin, M., & Mummery, C. L. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13577 · Cited by 121
Quantitative Disease, Drug, and Trial Models
Gobburu, J. V. S., & Lesko, L. J. (2008) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145613 · Cited by 124
DCDB 2.0: a major update of the drug combination database
Liu, Y., Wei, Q., Yu, G., Gai, W., Li, Y., & Chen, X. (2014) · Database · doi:10.1093/database/bau124 · Cited by 133
“However, accumulating evidence has suggested that this one-drug-one-target model is limited in many aspects (2).”
BackgroundNavigating the complexities of drug development for inflammatory bowel disease
Honap, S., Jairath, V., Danese, S., & Peyrin‐Biroulet, L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00953-0 · Cited by 138
“Approximately 96% of drugs fail to get past the early stages of development 30,31 .”
Human embryonic stem cell technologies and drug discovery
Jensen, J., Hyllner, J., & Björquist, P. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21732 · Cited by 122
“Several studies support that differentiation of embryonic stem cells into mature tissue can be improved by using 3D matrixes (Levenberg et al., 2003; Gerecht-Nir et al., 2004).”
BackgroundHigh-Content Assays for Hepatotoxicity Using Induced Pluripotent Stem Cell–Derived Cells
Sirenko, O., Hesley, J., Rusyn, I., & Cromwell, E. F. (2014) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2013.520 · Cited by 123
“velopment pipeline, or drugs being withdrawn after approval.(1) Drug safety is one of the primary concerns of drug”
Gregory, K. J., Dong, E. N., Meiler, J., & Conn, P. J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.007 · Cited by 119
“Thus, allosteric modulation represents an exciting novel means of targeting GPCRs particularly for CNS disorders, a therapeutic area with one of the highest rates of attrition in drug discovery (Kola and Landis, 2004).”
BackgroundAssessment of the Embryonic Stem Cell Test and application and use in the pharmaceutical industry
Paquette, J. A., Kumpf, S. W., Streck, R. D., Thomson, J. J., Chapin, R. E., & Stedman, D. B. (2008) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20148 · Cited by 122
Designing Drugs to Avoid Toxicity
Smith, G. F. (2011) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-381290-2.00001-x · Cited by 137
Peptide aptamers as guides for small-molecule drug discovery
Baines, I., & Colas, P. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.007 · Cited by 138
Kell, D. B. (2013) · The FEBS Journal · doi:10.1111/febs.12268 · Cited by 121
Strategies to assess blood–brain barrier penetration
Di, L., Kerns, E. H., & Carter, G. T. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.6.677 · Cited by 122
“For example, CNS candidates have an 8% success rate and a 12 – 16 year development time versus non-CNS drugs, which have an 11% success rate and a 10 – 12 year development time [3,4] .”
BackgroundRigor and reproducibility in rodent behavioral research
Gulinello, M. E., Mitchell, H. A., Chang, Q., O’Brien, W. T., Zhou, Z., Abel, T. G., Wang, L., Corbin, J. G., Veeraragavan, S., Samaco, R. C., et al. (2018) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2018.01.001 · Cited by 134
The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions
Polamreddy, P., & Gattu, N. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.022 · Cited by 130
The adult human brain in preclinical drug development
Dragunow, M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2617 · Cited by 119
Assessing the translatability of drug projects: what needs to be scored to predict success?
Wehling, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2898 · Cited by 121
“Aspect Weight (W: %)‡ score§ (s: 1–5) ∑ (S xW/ 100)§ Typical features for weak score (1) Typical features for strong score (5)”
BackgroundChen, M., Hong, H., Fang, H., Kelly, R., Zhou, G., Borlak, J., & Tong, W. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft189 · Cited by 115
“, 2010; Watkins, 2011) due to about 90% of drug candidates approved for human testing failing in clinical trials (Kola and Landis, 2004).”
Booth, R., & Kim, H. (2014) · Annals of Biomedical Engineering · doi:10.1007/s10439-014-1086-5 · Cited by 132
Ledwith, B. J., & DeGeorge, J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.273 · Cited by 120
Binding kinetics of ligands acting at GPCRs
Sykes, D. A., Stoddart, L. A., Kilpatrick, L. E., & Hill, S. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.01.018 · Cited by 138
“Many of these remaining GPCRs have been implicated in a variety of diseases and there have been many attempts to generate compounds that act at these receptors but many have failed in clinical trials often due to a lack of efficacy (Kola and Landis, 2004; Waring et al., 2015).”
Fraczek, J., Bolleyn, J., Vanhaecke, T., Rogiers, V., & Vinken, M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0983-3 · Cited by 119
“Indeed, in the early 90s, unsatisfactory efficacy and pharmacokinetics were identified as the most prominent causes of drug attrition (Kola and Landis 2004; Schuster et al. 2005).”
BackgroundInfluentialModeling Reactivity to Biological Macromolecules with a Deep Multitask Network
Hughes, T. B., Dang, N. L., Miller, G. P., & Swamidass, S. J. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00162 · Cited by 118
“3,4 Moreover, drug-induced liver injury (DILI) is the most frequent reason drugs are withdrawn from the market and causes 50% of acute liver failure cases in the United States.”
Lalu, M. M., Sullivan, K., Mei, S. H. J., Moher, D., Straus, A., Fergusson, D. A., Stewart, D. J., Jazi, M., Macleod, M. R., Winston, B. W., et al. (2016) · eLife · doi:10.7554/elife.17850 · Cited by 133
“, 2003) and only 11% of clinically tested agents receive licensing (Kola and Landis, 2004).”
BackgroundMichino, M., Beuming, T., Donthamsetti, P., Newman, A. H., Javitch, J. A., & Shi, L. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009944 · Cited by 118
A high content screening assay to predict human drug-induced liver injury during drug discovery
Persson, M., Løye, A. F., Mow, T. J., & Hornberg, J. J. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.08.001 · Cited by 120
Viđarsson, H., Hyllner, J., & Sartipy, P. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9113-x · Cited by 128
“The pharmaceutical industry suffers from late stage attrition mainly due to lack of efficacy and unexpected safety issues of new compounds [67].”
BackgroundExploratory toxicology as an integrated part of drug discovery. Part I: Why and how
Hornberg, J. J., Laursen, M., Brenden, N., Persson, M., Thougaard, A., Toft, D. B., & Mow, T. J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.008 · Cited by 125
Iskar, M., Zeller, G., Blattmann, P., Campillos, M., Kuhn, M., Kaminska, K. H., Runz, H., Gavin, A., Pepperkok, R., van Noort, V., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.20 · Cited by 118
“Understanding the complex responses of the human body to drug treatments is vitally important to address the efficacy and safety-related issues of compounds in later stages of drug development and, thus, to reduce high attrition rates in clinical trials (Kola and Landis, 2004).”
BackgroundPredictive approaches for drug combination discovery in cancer
Madani Tonekaboni, S. A., Soltan Ghoraie, L., Manem, V. S. K., & Haibe-Kains, B. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbw104 · Cited by 115
Cancer drug development: The missing links
Kunnumakkara, A. B., Bordoloi, D., Sailo, B. L., Roy, N. K., Thakur, K. K., Banik, K., Shakibaei, M., Gupta, S. C., & Aggarwal, B. B. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219839163 · Cited by 112
“In the United States, drug costs are also the focus of political discourse.(48) It is imperative that this problem is addressed throughout the entire drug development process in order to improve efficiency which will consequently benefit the patients with more profitable drugs.”
BackgroundSubtype‐selective targeting of voltage‐gated sodium channels
England, S., & de Groot, M. J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00437.x · Cited by 129
“However, in the 10 year period between 1991 and 2000, the average success rate (from first in man to registration) for new chemical entities in all therapeutic areas combined, was 11% (Kola and Landis, 2004).”
BackgroundLincecum, J. M., Vieira, F. G., Wang, M. Z., Thompson, K., Zutter, G. S. D., Kidd, J. D., Moreno, A., Sànchez, R., Carrion, I. J., Levine, B. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.557 · Cited by 125
“557" language="eng" relation="no"> Developing drugs, from target discovery to commercialization, is inefficient and has a high attrition rat”
BackgroundHow molecular profiling could revolutionize drug discovery
Stoughton, R. B., & Friend, S. H. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1696 · Cited by 118
Oral Particle Uptake and Organ Targeting Drives the Activity of Amphotericin B Nanoparticles
Serrano, D. R., Lalatsa, A., Dea‐Ayuela, M. A., Bilbao-Ramos, P. E., Garrett, N., Moger, J., Guarro, J., Capilla, J., Ballesteros, M. P., Schätzlein, A. G., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500527x · Cited by 117
Mechanisms of Hybrid Governance: Administrative Committees in Non-Equity Alliances
Reuer, J. J., & Devarakonda, S. V. (2015) · Academy of Management Journal · doi:10.5465/amj.2012.0098 · Cited by 145
Pharmacokinetic profile that reduces nephrotoxicity of gentamicin in a perfused kidney-on-a-chip
Kim, S., LesherPerez, S. C., Kim, B. C. C., Yamanishi, C., Labuz, J. M., Leung, B., & Takayama, S. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/015021 · Cited by 115
Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery
Lungare, S., Hallam, K., & Badhan, R. K. S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.042 · Cited by 120
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“However, almost 90% of compounds that pass through preclinical drug screening end up failing during clinical trials, and one-third of these failures have been attributed to toxicity.(3) Furthermore, ~90% of withdrawals of drugs from the marketplace are due to toxicity issues.”
BackgroundApplications of mass spectrometry in drug metabolism: 50 years of progress
Wen, B., & Zhu, M. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.1001029 · Cited by 116
“In 1991, attrition due to inappropriate pharmacokinetics and/or bioequivalence was 40%, and this figure was reduced to less than 10% by 2000 (Kola & Landis, 2004).”
BackgroundCancer Modeling‐on‐a‐Chip with Future Artificial Intelligence Integration
Fetah, K., DiPardo, B. J., Kongadzem, E.-M. L., Tomlinson, J. S., Elzagheid, A. I., Elmusrati, M. S., Khademhosseini, A., & Ashammakhi, N. A. (2019) · Small · doi:10.1002/smll.201901985 · Cited by 121
Toxicity testing in the 21st century beyond environmental chemicals
Rovida, C. (2015) · ALTEX · doi:10.14573/altex.1506201 · Cited by 106
Drug and Drug Candidate Building Block Analysis
Wang, J., & Hou, T. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900398f · Cited by 116
Microfluidic devices for in vitro studies on liver drug metabolism and toxicity
van Midwoud, P. M., Verpoorte, E., & Groothuis, G. M. M. (2011) · Integrative Biology · doi:10.1039/c0ib00119h · Cited by 115
Systems biology and its application to the understanding of neurological diseases
Villoslada, P., Steinman, L., & Baranzini, S. E. (2009) · Annals of Neurology · doi:10.1002/ana.21634 · Cited by 126
“Notably, this approach has been followed by the pharmaceutical industry, despite a remarkably low rate of success (only 11% of new therapeutic targets reach the market as new drugs).(4) Systems biology focuses on understanding not only the components of a given system, thus complementing the reductionist approach, but…”
BackgroundCait, J., Cait, A., Scott, R. W., Winder, C. B., & Mason, G. J. (2022) · BMC Biology · doi:10.1186/s12915-021-01184-0 · Cited by 134
An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics
LoRusso, P. M., Boerner, S. A., & Seymour, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1993 · Cited by 118
“Only 1 in 20 oncology drugs that enter clinical trials ever make it to commercial use, despite presumed continued improvements in preclinical drug discovery tools and increased investment in preclinical research (3).”
BackgroundInfluentialRefinement of Experimental Design and Conduct in Laboratory Animal Research
Bailoo, J. D., Reichlin, T. S., & Wurbel, H. (2014) · ILAR Journal · doi:10.1093/ilar/ilu037 · Cited by 107
“A 10-year review (1991–2000) of drug development revealed that the main causes of such attrition at the clinical trials stage are lack of efficacy and safety, which together account for 60% of the overall attrition rate (Kola and Landis 2004).”
BackgroundZhang, L., Wang, C.-C., & Chen, X. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac468 · Cited by 116
Stepan, A. F., Mascitti, V., Beaumont, K. C., & Kalgutkar, A. S. S. (2012) · MedChemComm · doi:10.1039/c2md20317k · Cited by 119
Some recommendations for multi-arm multi-stage trials
Wason, J. M. S., Magirr, D., Law, M., & Jaki, T. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280212465498 · Cited by 128
“Bringing a drug from the laboratory to the market is a long and expensive process often ending in failure.(1) Typically, a novel medicinal product will take 10–15 years to develop and validate, at the cost of hundreds of millions of dollars.”
Lu, J., Einhorn, S., Venkatarangan, L., Miller, M., Mann, D. A., Watkins, P. B., & LeCluyse, E. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv117 · Cited by 112
“Drug-induced liver injury (DILI) accounts for a large percentage of drug candidate failures and traditional laboratory animal-based models are not sufficiently predictive of DILI in humans (Kola and Landis, 2004; Ledford, 2011; Navarro and Senior, 2006).”
BackgroundStrategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 116
“Introduction The process of novel drug development from first-inhuman studies to registration phase III clinical trials is associated with an unacceptably high attrition rate [1].”
BackgroundYao, Y., Zhang, X., Wang, Z., Zheng, C., Li, P., Huang, C., Tao, W., Xiao, W., Wang, Y., Huang, L., et al. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.09.018 · Cited by 118
“It is known that poor pharmacokinetics accounts for about 30% attrition in drug development process (Kola and Landis, 2004).”
BackgroundNMR metabolomics and drug discovery
Powers, R. (2009) · Magnetic Resonance in Chemistry · doi:10.1002/mrc.2461 · Cited by 134
Gleeson, M. P., Bravi, G., Modi, S. P., & Lowe, D. M. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.07.002 · Cited by 111
Safety and secondary pharmacology: Successes, threats, challenges and opportunities
Valentin, J., & Hammond, T. G. (2008) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2008.05.007 · Cited by 112
“Over the same period, both non-clinical and clinical safety has remained the major cause of drug attrition during clinical development and of withdrawal of marketed drugs; accounting for approximately 35 to 40% of all drug discontinuation (Kennedy, 1997; Lasser et al., 2002; Kola & Landis, 2004).”
BackgroundIntroducing Therioepistemology: the study of how knowledge is gained from animal research
Garner, J. P., Gaskill, B. N., Weber, E. M., Dallaire, J. A., & Pritchett‐Corning, K. R. (2017) · Lab Animal · doi:10.1038/laban.1224 · Cited by 115
Gentamicin induced acute renal damage and its evaluation using urinary biomarkers in rats
Udupa, V., & Prakash, V. (2018) · Toxicology Reports · doi:10.1016/j.toxrep.2018.11.015 · Cited by 123
Trends in the Use and Role of Biomarkers in Phase I Oncology Trials
Goulart, B. H. L., Clark, J. W., Pien, H. H., Roberts, T. G., Finkelstein, S. N., & Chabner, B. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2860 · Cited by 111
Phase 0 Clinical Trials: Conceptions and Misconceptions
Kummar, S., Rubinstein, L., Kinders, R., Parchment, R. E., Gutierrez, M. E., Murgo, A. J., Ji, J., Mroczkowski, B., Pickeral, O. K., Simpson, M., et al. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d6f3 · Cited by 110
“The FDAs exploratory IND guidance provides 3 general examples of early-phase clinical trials that address (1) PK or imaging, (2) pharmacologically relevant doses, and (3) evaluation of an agent’s mechanism of action.”
BackgroundThe Valley of Death in anticancer drug development: a reassessment
Adams, D. J. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.001 · Cited by 106
“Commercial issues Alignment of corporate R&D with marketing goals; awareness of competitor programs; over-management of R&D by those lacking scientific-medical expertise; resources focused on marketing [14, 107]”
BackgroundInfluentialAnticancer Activity of Limonene: A Systematic Review of Target Signaling Pathways
Araújo‐Filho, H. G. D., dos Santos, J. F., Carvalho, M. T. B., Picot, L., Fruitier‐Arnaudin, I., Groult, H., Quintans‐Júnior, L. J., & Quintans, J. S. S. (2021) · Phytotherapy Research · doi:10.1002/ptr.7125 · Cited by 110
“Given that the discovery of new drugs is not a simple process, in cancer, the obstacles that the researcher must face are even greater (Kola & Landis, 2004).”
BackgroundDengue drug discovery: Progress, challenges and outlook
Lim, S. P. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.12.016 · Cited by 118
“Besides the lack of efficacy, lack of safety is another common cause of attrition during drug development (Kola and Landis, 2004) and in clinical trials (Harrison, 2016).”
BackgroundBasavaraj, S., & Betageri, G. V. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.12.003 · Cited by 133
Hong, M., Li, S., Wang, N., Tan, H., Cheung, F., & Feng, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030620 · Cited by 110
“Currently, the most important problem for novel drugs development is a lack of therapeutic efficacy in clinical trials, which account for 33% of failures [19].”
Background
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.